<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00571818</url>
  </required_header>
  <id_info>
    <org_study_id>114-00FB</org_study_id>
    <nct_id>NCT00571818</nct_id>
  </id_info>
  <brief_title>The Prospective Evaluation of Pancreatic Function in Pancreas Transplant Recipients</brief_title>
  <official_title>The Prospective Evaluation of Pancreatic Function in Pancreas Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand how the pancreas functions after transplantation&#xD;
      and particularly why high blood sugar levels develop. It will also analyze the effect of the&#xD;
      medicines used to prevent rejection on blood sugar levels.&#xD;
&#xD;
      The hypothesis to be tested is that hyperglycemia more than six months after successful&#xD;
      pancreas transplant results from a defect in insulin secretion, insulin resistance, or both.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type I diabetes mellitus (DM1) is an autoimmune disease characterized by destruction of the&#xD;
      in sulin-secreting beta cells. Insulin replacement has been the cornerstone of therapy for&#xD;
      patients with DM1. However, pancreas transplantation, utilizing the whole pancreas as a means&#xD;
      to replace the destroyed beta cells, has become a therapeutic alternative. The goal of&#xD;
      pancreas transplantation is the establishment of long-term euglycemia, thereby preventing or&#xD;
      allowing for the repair of end-organ complications.&#xD;
&#xD;
      Maintenance of the pancreas allograft over many years remains the goal in following pancreas&#xD;
      transplant recipients over time. The onset of hyperglycemia less than one year after&#xD;
      transplant is usually due to issues of surgical technique or acute rejection. HOwever, the&#xD;
      onset of hyperglycemia fter one year of pancreas transplant is more problematic because the&#xD;
      underlying causes are less clear and have been less well characterized. Currently, there is&#xD;
      no protocol for definitively identifying the causes of hyperglycemia in pancreas transplant&#xD;
      recipients over one year. This project will systematically characterize beta cell function&#xD;
      and peripheral tissue response to insulin in patients who have received an earlier successful&#xD;
      pancreas transplant who have developed hyperglycemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate beta cell secretion, insulin sensitivity, and glucose effectiveness, in euglycemic &amp; hyperglycemic pancreas transplant pts,&amp; euglycemic kidney transplant pts at least 9 months post-transplant as well as normal controls.</measure>
    <time_frame>two visits</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Transplant</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>EP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EK</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Oral glucose tolerance test</intervention_name>
    <description>test done over 2 hours</description>
    <arm_group_label>EK</arm_group_label>
    <arm_group_label>EP</arm_group_label>
    <arm_group_label>HC</arm_group_label>
    <arm_group_label>HP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IV Glucose Tolerance Test</intervention_name>
    <description>Done over 4 hours</description>
    <arm_group_label>EK</arm_group_label>
    <arm_group_label>EP</arm_group_label>
    <arm_group_label>HC</arm_group_label>
    <arm_group_label>HP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hyperglycemic pancreas transplant recipients:&#xD;
&#xD;
               -  ages 19-65&#xD;
&#xD;
               -  received a pancreas transplant ≥ 9 months previously&#xD;
&#xD;
               -  fasting glucose levels ≥ 126 mg/dl&#xD;
&#xD;
               -  hemoglobin A1C &gt; 1% above normal&#xD;
&#xD;
          -  Euglycemic pancreas transplant recipients:&#xD;
&#xD;
               -  ages 19-65&#xD;
&#xD;
               -  received a pancreas transplant ≥ 9 months previously&#xD;
&#xD;
               -  fasting glucose levels are &lt; 126 mg/dl&#xD;
&#xD;
               -  normal HbA1C without taking any medications for the treatment of high blood&#xD;
                  sugars.&#xD;
&#xD;
          -  Euglycemic Kidney Transplant Recipients:&#xD;
&#xD;
               -  ages 19-65&#xD;
&#xD;
               -  no prior diagnosis of diabetes&#xD;
&#xD;
               -  received a kidney transplant ≥ 9 months previously&#xD;
&#xD;
               -  showing continued function&#xD;
&#xD;
          -  Euglycemic Healthy Control Subjects:&#xD;
&#xD;
               -  ages 19-65&#xD;
&#xD;
               -  no diabetes or renal disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hyperglycemic pancreas transplant recipients:&#xD;
&#xD;
               -  chronic illnesses that would decrease insulin sensitivity (&#xD;
&#xD;
               -  terminal illness&#xD;
&#xD;
               -  BMI &gt; 30 kg/m2&#xD;
&#xD;
               -  serum creatinine &gt; 2 mg/dl&#xD;
&#xD;
               -  hemoglobin &lt; 10 g/dl&#xD;
&#xD;
               -  an episode of acute rejection with the preceding 3 months of entry.&#xD;
&#xD;
          -  Euglycemic pancreas transplant recipients:&#xD;
&#xD;
               -  Exclusion criteria are the same as with hyperglycemic transplant patients.&#xD;
&#xD;
               -  no diagnosis of type 2 diabetes.&#xD;
&#xD;
          -  Euglycemic Kidney Transplant Recipients:&#xD;
&#xD;
               -  Exclusion criteria are the same as for euglycemic pancreas transplant recipients&#xD;
                  above.&#xD;
&#xD;
          -  Euglycemic Healthy Control Subjects:&#xD;
&#xD;
               -  chronic illnesses&#xD;
&#xD;
               -  medications known to affect glucose metabolism&#xD;
&#xD;
               -  a history of smoking&#xD;
&#xD;
               -  serum creatinine ≥ 1.5 mg/dl&#xD;
&#xD;
               -  BMI &gt; 30 kg/m2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James T. Lane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>December 11, 2007</study_first_submitted>
  <study_first_submitted_qc>December 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2007</study_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>euglycemic</keyword>
  <keyword>transplant</keyword>
  <keyword>pancreas</keyword>
  <keyword>hyperglycemic</keyword>
  <keyword>kidney</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

